Efficacy and safety of albumin-bound paclitaxel combined with nedaplatin followed by concurrent radiotherapy in tretment of massive cervical cancer
10.3760/cma.j.cn115355-20210126-00057
- VernacularTitle:白蛋白结合型紫杉醇联合奈达铂同步放疗治疗巨块型子宫颈癌的效果及安全性
- Author:
Lina WANG
1
;
Yuxia WANG
;
Le WANG
;
Hong JIN
;
Kejin HUANG
;
Qi LI
;
Haiyan CHENG
Author Information
1. 哈尔滨医科大学附属肿瘤医院妇瘤科，哈尔滨 150081
- Keywords:
Cervical neoplasms;
Albumin-bound paclitaxel;
Massive cervical cancer;
Radiotherapy;
Drug therapy, combination
- From:
Cancer Research and Clinic
2021;33(6):419-422
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the short-term efficacy and safety of albumin-bound paclitaxel combined with nedaplatin followed by concurrent radiotherapy in treatment of stage Ⅲ massive cervical cancer.Methods:The clinical data of 84 patients with massive cervical cancer admitted to Harbin Medical University Cancer Hospital from April 2019 to April 2020 were retrospectively analyzed. According to the different treatment regimens, patients were divided into the observation group and the control group, each with 42 cases. The observation group received albumin-bound paclitaxel combined with nedaplatin followed by concurrent radiotherapy, and the control group received solvent-based paclitaxel combined with nedaplatin followed by concurrent radiotherapy. The short-term efficacy and adverse reactions of the two groups were compared.Results:The partial remission (PR) rate of the observation group and the control group at 1 month of treatment was 92.9% (39/42) and 35.7% (15/42), respectively, and the difference was statistically significant ( χ2 = 29.867, P < 0.01). The complete remission (CR) rate of the observation group and the control group at 1 month after treatment was 59.5% (25/42) and 38.1% (16/42), respectively, and the difference was statistically significant ( χ2 = 3.859, P = 0.049). The incidence of diarrhea of the observation group was lower than that of the control group [33.33% (14/42) vs. 54.8% (23/42)], and the difference was statistically significant ( χ2 = 3.913, P = 0.048). There were no statistical differences in the incidence of hematological adverse reactions and abnormal liver and kidney functions between the two groups (all P > 0.05). Conclusion:The albumin-bound paclitaxel combined with nedaplatin followed by concurrent radiotherapy have a good short-term efficacy in treatment of stage Ⅲ massive cervical cancer, and the adverse reactions are tolerable.
